Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To estimate overall rates of adherence, persistence, and discontinuation for patients with type 2 diabetes mellitus (T2DM) prescribed oral antihyperglycemic agents (OAHAs) by combining results of published studies. RESEARCH DESIGN AND METHODS: A systematic literature review was conducted to identify articles published in English over the last 10 years evaluating the use of OAHAs for the treatment of T2DM. Databases searched included PubMed/MEDLINE, EMBASE, and the Cochrane Library. Seventy studies reporting adherence, persistence or discontinuation were identified by two independent reviewers and 40 reported relevant endpoints for the analysis. Outcomes included: (1) mean adherence defined as the average medication possession ratio (MPR); (2) proportion of adherent patients (MPR ≥ 80%); (3) discontinuation; and (4) persistence. Adherence and persistence were reported in observational studies only. Discontinuation was examined separately in randomized controlled trials (RCTs) and observational studies. Meta-analyses were conducted using both fixed and random effects models. When meta-analysis was not appropriate for a given outcome, descriptive statistics were provided. RESULTS: The pooled mean MPR (95% confidence interval [CI]) was 75.3% (68.8%-81.7%; n = 13) and the proportion of adherent patients (95% CI) was 67.9% (59.6%-76.3%; n = 12). The discontinuation rate (95% CI) in RCTs was 31.8% (17.0%-46.7%; n = 7). Persistence and discontinuation were not assessed via meta-analysis for observational studies due to the limited number of available studies and differences in outcome definitions. In these studies, persistence estimates ranged from 41.0% to 81.1%, with a mean (95% CI) of 56.2% (46.1%-66.3%; n = 6), while discontinuation estimates ranged from 9.9% to 60.1%, with a mean (95% CI) of 31.4% (17.6%-45.3%; n = 6). LIMITATIONS: Limitations include (1) the use of MPR as a proxy for adherence, (2) limited number of studies available, and (3) observed heterogeneity. CONCLUSION: The results of the analysis demonstrate that medication adherence, persistence, and discontinuation rates are suboptimal in patients with T2DM prescribed OAHAs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Suboptimal medication-taking behavior and low rates of continued medication use, or what is termed ' persistence to therapy plans, ' affects almost half of people with type 2 diabetes, leading to suboptimal glycemic and CVD risk factor control as well as increased risks of diabetes complications, mortality, and hospital admissions and increased health care costs (58 -62).”
In the citing paper
“Suboptimal medication-taking behavior and low rates of continued medication use, or what is termed ' persistence to therapy plans, ' affects almost half of people with type 2 diabetes, leading to suboptimal glycemic and CVD risk factor control as well as increased risks of diabetes complications, mortality, and hospital admissions and increased health care costs (58 -62).”
In the citing paper
“For example, adherence rates for major antidiabetic medications and antihypertensive medications are approximately 68% and 55%, respectively”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [74]
In the citing paper
“A meta-analysis of oral AHAs reported the pooled mean medication possession ratio (MPR) to be 75.3% over 6–24 months of follow-up.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [22]
In the citing paper
“In one recent meta-analysis that included randomized clinical trials of patients with T2D, persistence rates ranged from 41% to 81% and discontinuation rates ranged from 10% to 61% over a 12-month follow-up.21”
From Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors (2016) · cites this paper as [21]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“Meta-analysis The outcomes of interest for the meta-analysis were (1) mean adherence, defined as the average medication possession ratio (MPR); (2) proportion of adherent patients, defined as MPR 80%; (3) discontinuation, defined as the proportion of patients who discontinued medication use during the study period; an…”
BackgroundMethodIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220
Fu, R., Gartlehner, G., Grant, M., Shamliyan, T., Sedrakyan, A., Wilt, T. J., Griffith, L., Oremus, M., Raina, P., Ismaila, A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.08.010 · Cited by 730
Barriers to diabetes management: patient and provider factors
Nam, S., Chesla, C., Stotts, N. A., Kroon, L., & Janson, S. L. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.02.002 · Cited by 680
Cramer, J. A., Benedict, Á., Muszbek, N., Keskinaslan, A., & Khan, Z. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01630.x · Cited by 487
Raebel, M. A., Schmittdiel, J., Karter, A. J., Konieczny, J. L., & Steiner, J. F. (2013) · Medical Care · doi:10.1097/mlr.0b013e31829b1d2a · Cited by 485
Donnan, P. T., MacDonald, T. M., & Morris, A. D. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00689.x · Cited by 437
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
Lau, D. T., & Nau, D. P. (2004) · Diabetes Care · doi:10.2337/diacare.27.9.2149 · Cited by 318
Oral antidiabetic medication adherence and glycemic control in managed care.
Rozenfeld, Y., Hunt, J. S., Plauschinat, C. A., & Wong, K. S. (2008) · PubMed · Cited by 299
Taskinen, M. ‐., Rosenstock, J., Tamminen, I., Kubiak, R., Patel, S., Dugi, K. A., & Woerle, H. ‐. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01326.x · Cited by 294
Medication Taking and Diabetes
Odegard, P. S., & Capoccia, K. (2007) · The Diabetes Educator · doi:10.1177/0145721707308407 · Cited by 273
Medication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based Study
Tiv, M., Viel, J.-F., Mauny, F., Eschwège, E., Weill, A., Fournier, C., Fagot-Campagna, A., & Penfornis, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032412 · Cited by 245
Hertz, R. P., Unger, A. N., & Lustik, M. B. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.009 · Cited by 185
Predictors of medication adherence in patients with type 2 diabetes mellitus
Curkendall, S. M., Thomas, N., Bell, K. F., Juneau, P. L., & Weiss, A. J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.821056 · Cited by 148
Filozof, C., & Gautier, J. ‐. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02938.x · Cited by 145
Cheong, C., Barner, J. C., Lawson, K. A., & Johnsrud, M. T. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.10.003 · Cited by 95
Pfützner, A., Paz‐Pacheco, E., Allen, E., Frederich, R., Chen, R., & for the CV181039 Investigators (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01385.x · Cited by 93
Rathmann, W., Kostev, K., Gruenberger, J. B., Dworak, M., Bader, G., & Giani, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01674.x · Cited by 93
Depression in Patients with Type 2 Diabetes: Impact on Adherence to Oral Hypoglycemic Agents
Kalsekar, I. D., Madhavan, S. S., Amonkar, M. M., Makela, E. H., Scott, V. G., Douglas, S. M., & Elswick, B. L. M. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g606 · Cited by 85
Goldstein, B. J., Rosenstock, J., Anzalone, D. A., Tou, C., & Öhman, K. P. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x154169 · Cited by 75
Blonde, L., Wogen, J., Kreilick, C., & Seymour, A. A. (2003) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00297.x · Cited by 73
Hansen, R. A., Farley, J. F., Droege, M., & Maciejewski, M. L. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.07.011 · Cited by 68
Nichols, G. A., Conner, C., & Brown, J. B. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.504396 · Cited by 49
Medication Adherence Affects Treatment Modifications in Patients With Type 2 Diabetes
Voorham, J., Haaijer‐Ruskamp, F. M., Wolffenbuttel, B. H. R., Stolk, R. P., & Denig, P. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.024 · Cited by 49
Jain, R., Osei, K., Kupfer, S., Perez, A. T., Zhang, J., & Lannon, M. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.10.1388 · Cited by 47
Barron, J. O., Wahl, P. M., Fisher, M. D., & Plauschinat, C. A. (2008) · PubMed · Cited by 42
Barner, J. C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.07.016 · Cited by 32
Pollack, M., Chastek, B., & Williams, S. (2009) · Value in Health · doi:10.1016/s1098-3015(10)73579-8 · Cited by 31
Compliance and persistence with concomitant statin and oral antihyperglycemic therapy.
Zhang, Q., Zhao, C., Davies, M. J., Radican, L., & Seck, T. L. (2011) · PubMed · Cited by 28
Self-citationEffect of non-persistent use of oral glucose-lowering drugs on HbA1cgoal attainment
Beest, F. J. A. P., van der Bij, S., Erkens, J. A., Kessabi, S., Groot, M. T., & Herings, R. M. C. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802336335 · Cited by 27
Virdi, N., Daskiran, M., Nigam, S., Kozma, C., & Raja, P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0047 · Cited by 27
Sustained Hyperglycemia Among Patients With Diabetes
Lafata, J. E., Dobie, E., Divine, G., Yood, M. U., & McCarthy, B. D. (2009) · Diabetes Care · doi:10.2337/dc08-2028 · Cited by 25
Kasliwal, R., Wilton, L., & Shakir, S. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00003 · Cited by 24
Refill adherence to oral antihyperglycaemic drugs in Sweden
Haupt, D. W., Weitoft, G. R., & Nilsson, J. L. G. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0076-1 · Cited by 23
Feinböck, C., Luger, A., Klingler, A., Egger, T., Bielesz, G., Winkler, F., Siebenhofer, A., Großschädl, F., Frank, E., & Irsigler, K. (2003) · PubMed · Cited by 22
Truitt, K. E., Goldberg, R. B., Rosenstock, J., Chou, H. S., Merante, D., Triscari, J. M., & Wang, A. C. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003715079 · Cited by 17
Balkrishnan, R., Rajagopalan, R., Shenolikar, R. A., Camacho, F., & Anderson, R. T. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x96263 · Cited by 15
Change of initial oral antidiabetic therapy in type 2 diabetic patients
Plat, A. W., Beest, F. P.-V., Kessabi, S., Groot, M. T., & Herings, R. M. C. (2009) · Pharmacy World & Science · doi:10.1007/s11096-009-9321-0 · Cited by 15
Discontinuation of statins among patients with type 2 diabetes
Lamberts, E. J. F., Nijpels, G., Welschen, L. M. C., Hugtenburg, J. G., Dekker, J. M., Souverein, P. C., & Bouvy, M. L. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1293 · Cited by 13
Nau, D. P., Chao, J., & Aikens, J. E. (2005) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2005.06.001 · Cited by 12
Medication adherence in low income elderly type-2 diabetes patients: A retrospective cohort study
Patel, I., Chang, J., Shenolikar, R. A., & Balkrishnan, R. (2010) · International Journal of Diabetes Mellitus · doi:10.1016/j.ijdm.2010.05.003 · Cited by 12
Wong, M. C. S., Kong, A. P. S., So, W., Tse, S. L. A., Wang, H., Jiang, J. Y., Chan, J. C. N., & Griffiths, S. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.01.012 · Cited by 6
Measuring Persistence to Oral Hypoglycemic Agents in Type 2 Diabetic Veterans
Kim, N. V., Agostini, J. V., & Justice, A. C. (2009) · Journal of Pharmacy Technology · doi:10.1177/875512250902500402 · Cited by 2
Research works printed but not linked: 7
- International Diabetes Federation, 2014, IDF Diabetes Atlas update poster
- Amiche MA, 2012, J Popul Ther Clin Pharmacol, 19, e115
- Barron J, 2008, PT, 33, 532
- Pollack M, 2010, J Clin Outcomes Manage, 17, 20
- Rozenfeld Y, 2008, Am J Manag Care, 14, 71
- Zhang Q, 2011, Am J Manag Care, 17, 746
- Feinbock C, 2003, Diabetes Nutr Metab, 16, 214
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Polonsky, W., & Henry, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106821 · Cited by 784
“21 Another commonly used metric is medication persistence.”
Metadata
- Authors
- Iglay, K., Cartier, S. E., Rosen, V. M., Zarotsky, V., Rajpathak, S. N., Radican, L., & Tunceli, K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Optum (United States) (US)
- Corresponding author
- Iglay, Kristy
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2015-06-18
- Volume
- 31
- Issue
- 7
- Pages
- 1283-1296
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W1837867596
- Cited by
- 157
- References
- 53
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 13 · 2023: 13 · 2022: 23 · 2021: 14 · 2020: 15 · 2019: 19 · 2018: 16 · 2017: 11 · 2016: 9
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- medication adherence, treatment persistence, drug discontinuation, oral antidiabetic drugs, type 2 diabetes, medication possession ratio, diabetes treatment, randomized controlled trials, quality of life, glycemic control, cost-effectiveness
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Drug Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.